Literature DB >> 24785234

About the validation of animal models to study the pharmacodynamics of generic antimicrobials.

Andres F Zuluaga1, Carlos A Rodriguez1, Maria Agudelo1, Omar Vesga2.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24785234     DOI: 10.1093/cid/ciu306

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.

Authors:  Carlos A Rodriguez; Maria Agudelo; Andres F Zuluaga; Omar Vesga
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

2.  An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.

Authors:  Carlos A Rodriguez; Maria Agudelo; Javier M Gonzalez; Omar Vesga; Andres F Zuluaga
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone.

Authors:  Ivone Jimenez-Toro; Carlos A Rodriguez; Andres F Zuluaga; Julian D Otalvaro; Omar Vesga
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

4.  Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.

Authors:  Andres F Zuluaga; Carlos A Rodriguez; Maria Agudelo; Omar Vesga
Journal:  BMC Res Notes       Date:  2015-10-07

5.  Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.

Authors:  Carlos A Rodriguez; Maria Agudelo; Yudy A Aguilar; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

6.  Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.

Authors:  Javier M Gonzalez; Carlos A Rodriguez; Andres F Zuluaga; Maria Agudelo; Omar Vesga
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.